Skip to content

BridgeBio 药

US · BBIO #1254 按市值排名 上市于 2019
66.39 -0.74 -1.10%
实时 - 追踪5344个代码 - 心跳于496秒前 · 2026-10-16 20:02

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了1家。
  • 机构持股总比例下降了2.3个百分点。

机构持股

机构持股比例
98.46% -2.34pp
机构数量
565 -1
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund56.65%
Hedge Fund24.41%
VC/PE Fund8.67%
Individual/Insider3.93%
Private Company3.84%
Public Company3.06%
Sovereign Wealth Fund0.87%
Government Pension Fund0.65%
Insurance Company0.23%

主要股东 截至 2026-06-30

Janus Henderson Group plc 7.22% · 14.11M 股
Farallon Capital Management, L.L.C. 5.50% · 10.74M 股
BlackRock 5.26% · 10.29M 股
Viking Global Investors LP 5.01% · 9.79M 股
Vanguard Capital Management, LLC 4.61% · 9.02M 股
KKR & Co. Inc. 4.23% · 8.26M 股
Vanguard Portfolio Management, LLC 3.92% · 7.66M 股
Wellington Management Group 2.72% · 5.31M 股
Neil Kumar 2.59% · 5.06M 股
Two Sigma Investments, LP 2.42% · 4.72M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 26次买入 · 24次卖出

姓名职务持股比例
Neil Kumar Chief Executive Officer 2.59%
Charles Homcy Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director 0.47%
Frank McCormick Co-Founder & Chairman of Oncology 0.39%
Thomas Trimarchi Chief Product Officer 0.17%
Ali Satvat Independent Director 0.08%
Maricel Apuli Chief Accounting Officer 0.06%
Brian Stephenson Chief Financial Officer 0.05%
James Momtazee Director 0.05%
Wen-Chaun Lo Independent Director 0.03%
Douglas Dachille Independent Director 0.01%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-16 Neil Kumar Chief Executive Officer Automatic Disposition -10,000 $69.01–69.57
2026-08-18 Neil Kumar Chief Executive Officer Automatic Disposition -44,980 $81.15–85.65
2026-08-17 Neil Kumar Chief Executive Officer Intent to Sell (Form 144) -34,980 $79.89
2026-08-16 Randal Scott Independent Director Intent to Sell (Form 144) -21,501 $79.86
2026-08-15 Neil Kumar Chief Executive Officer Derivative Exercise and Sale -36,237 $79.86
2026-08-15 Neil Kumar Chief Executive Officer Derivative Exercise and Retained +34,980 --
2026-08-15 Thomas Trimarchi Chief Product Officer Sale to Issuer -22,781 $79.86
2026-08-15 Maricel Apuli Chief Accounting Officer Sale to Issuer -4,714 $79.86
2026-07-29 Maricel Apuli Chief Accounting Officer Automatic Disposition -2,000 $80.06
2026-07-08 Jennifer Cook Director Derivative Exercise and Sale -148,589 $8.45–90.00
2026-07-08 Andrea Ellis Independent Director Derivative Exercise and Sale -17,167 $16.75–84.00
2026-06-23 Randal Scott Independent Director Intent to Sell (Form 144) -2,196 $68.63
2026-06-23 Jennifer Cook Director Derivative Exercise and Sale -37,167 $8.45–70.00
2026-06-22 Jennifer Cook Director Automatic Disposition -2,196 $68.57
2026-06-22 Hannah Valantine Independent Director Automatic Disposition -2,196 $68.57
2026-06-21 Charles Homcy Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director Other Acquisition +3,990 --
2026-06-21 Charles Homcy Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director Other Derivative Acquisition +5,277 $68.92
2026-06-21 Fred Hassan Independent Director Other Acquisition +3,990 --
2026-06-21 Fred Hassan Independent Director Other Derivative Acquisition +5,277 $68.92
2026-06-21 Ronald Daniels Independent Director Other Acquisition +3,990 --

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 20:02:27 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

BridgeBio 药 讨论区 0 条评论

发表评论